Liver Transplant From a Deceased Donor With Cystinosis: A Case Report by Raeda Taj, Kim Ng, Sanmati R. Cuddapah, Elizabeth B. Rand, Melissa Bleicher, Sandra Amaral, Maarouf A. Hoteit, Rajendar K. Reddy, Eyob Feyssa, Emma E. Furth, Kim M. Olthoff, Samir Abu‐Gazala, Matthew H. Levine, Frederick Vyas, Peter L. Abt

“…The liver was successfully transplanted into a 65‐year‐old female recipient with hepatitis C (HCV) cirrhosis. The recipient is currently 12 months post‐transplant and experiencing good graft function without evidence of cystine crystals on liver biopsy. …”
Get full text

Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel by V. V. Breder, R. B. Alikhanov, S. S. Bagnenko, E. N. Bessonova, V. A. Isakov, N. E. Kudashkin, B. M. Medvedeva, A. V. Mishchenko, M. S. Novruzbekov, V. S.  Rudakov

“…Screening for HCC in high-risk groups (cirrhosis of any etiology, patients with chronic viral hepatitis B and patients with F3 liver fibrosis) should be organized as regular (every 6 months) liver ultrasound in combination with determination of the serum alpha-fetoprotein (AFP) level. …”
Get full text

Incidence and risk factors for mortality of vertebral osteomyelitis: a retrospective analysis using the Japanese diagnosis procedure combination database by Hideo Yasunaga, Hirotaka Chikuda, Kiyohide Fushimi, Hiromasa Horiguchi, Toru Akiyama, Kazuo Saita

“…A higher rate of in-hospital mortality was significantly associated with haemodialysis use (ORs, 10.56 (95% CI 8.12 to 13.74)), diabetes (2.37 (1.89 to 2.98)), liver cirrhosis (2.63 (1.49 to 4.63)), malignancy (2.68, (2.10 to 3.42)) and infective endocarditis (3.19 (1.80 to 5.65)).Conclusions Our study demonstrates an increasing incidence of VO, and defines risk factors for death with a nationwide database. …”
Get full text

GB Virus C Infection: Clinical Significance by Xiang Wei Meng, Masafumi Komatsu, Shigetoshi Ohshima, Kunio Nakane, Tomoo Fujii, Takashi Goto, Kazuo Yoneyama, Tomoyuki Kuramitsu, Motokazu Mukaide

“…Among patients with the non-B, non-C type of chronic disease, one of seven with cirrhosis (14%) and none with chronic hepatitis or hepatocellular carcinoma were GBV-C-positive. …”
Get full text

Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease by Yunfei Wu, Yunfei Wu, Guojun Zheng, Guojun Zheng, Fan Zhang, Fan Zhang, Fan Zhang, Wenjian Li, Wenjian Li

“…Additionally, subgroup analyses were conducted to investigate the potential heterogeneity among different characteristic subgroups.ResultsThe results demonstrated a significant correlation between elevated hsCRP levels and an increased risk of significant fibrosis, advanced fibrosis, and cirrhosis in the US cohort of MASLD patients (OR 2.22, 1.69, and 2.85, respectively; all P <0.05). …”
Get full text

Real-world effectiveness of sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir against genotype 3 hepatitis C virus infection: a systematic r... by Liwei Zhuang, Liwei Zhuang, Junnan Li, Yu Zhang, Shibo Ji, Huichun Xing, Huichun Xing

“…The pooled SVR rate was 96.79% (95% CI: 93.37-99.13%) and 88.41% (95% CI: 82.67-93.22%) in treatment-naive and treatment-experienced patients, respectively.ConclusionSOF+VEL ± RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings. Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate.…”
Get full text

Right Gastroepiploic Artery as an Alternative for Arterial Reconstruction in Living Donor Liver Transplantation by Klaus Steinbrück, Reinaldo Fernandes, Marcelo Enne, Rafael Vasconcelos, Giuliano Bento, Gustavo Stoduto, Thomas Auel, Lúcio Filgueiras Pacheco-Moreira

“…A 62-year-old woman, with cirrhosis due to hepatitis B associated with hepatocellular carcinoma, was submitted to living donor liver transplantation. …”
Get full text

Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations by Amany Belal, Aly Abdou, Samar F. Miski, Mohamed A. M. Ali, Heba I. Ghamry, Ahmad J. Obaidullah, Ahmad J. Obaidullah, Mohamed Y. Zaky, Ahmed H. E. Hassan, Ahmed H. E. Hassan, Eun Joo Roh, Eun Joo Roh, Ahmed A. Al-Karmalawy, Ahmed A. Al-Karmalawy, Mona H. Ibrahim

“…HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), infects 4,000 people daily, potentially leading to 1.2 million new cases by 2025, while HCV chronically affects 58 million people, causing cirrhosis and hepatocellular carcinoma. Indole-based compounds play a crucial role in antiviral drug development due to their “privileged scaffold” structure. …”
Get full text

Long-Term Monitoring of Liver Fibrosis and Steatosis in Patients with Chronic Hepatitis C after Achieving a Sustained Virologic Response to Antiviral Therapy by K. R. Dudina, P. A. Belyy, I. V. Maev, N. Kh. Safiullina, E. A. Klimova, S. A. Shutko, O. O. Znoyko, N.  D. Yushchuk

“…In the long-term period after reaching SVR, regression of liver fibrosis was diagnosed in 80 % of cases (including in patients with cirrhosis), and the progression of fibrosis was in 3 % of patient. …”
Get full text

HCV and HBV genotypes: vital in the progression of HCV/ HBV co-infection by Yasmin Badshah, Maria Shabbir, Khushbukhat Khan, Sameen Zafar, Tayyaba Afsar, Fohad Mabood Husain, Houda Amor, Suhail Razak

“…Abstract Background Viral hepatitis is the major contributor to liver cirrhosis and hepatocellular carcinoma (HCC). Studies indicated that the co-infection of hepatitis C and hepatitis B virus also prompts liver damage progression. …”
Get full text

Circle-seq reveals that eccDNA may be a key blood biomarker for HBV-associated liver cancer by Xiao K. Ran, Xiao F. Zhao, Zhen W. Wei, Hua Z. Pang, Yan F. Tang, Rong Liu, Tie X. Wu, Xu D. Liu

“…Relevant eccDNA profiles have been established for various types of cancer; however, the eccDNA expression profiles in the blood of patients with hepatocellular carcinoma (HCC) and liver cirrhosis (LC) remain unknown. The present study aimed to investigate the eccDNA expression profiles in the blood of patients with HCC and LC.MethodsCircle-seq was used to detect eccDNAs in the blood samples. …”
Get full text

Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR by Ewa Wunsch, Marta Klak, Urszula Wasik, Malgorzata Milkiewicz, Malgorzata Blatkiewicz, Elzbieta Urasinska, Olivier Barbier, Dariusz Bielicki, Dimitrios P. Bogdanos, Elwyn Elias, Piotr Milkiewicz

“…We studied the PXR/SULT2A1 axis in chronic cholestatic conditions: primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). Materials/Methods. Western-blot/PCRs for SULT2A1/PXR were performed in PSC (n=11), PBC (n=19), and control liver tissues (n=19). …”
Get full text

Gallstone Ileus following Endoscopic Stone Extraction by Yoshiya Yamauchi, Noritaka Wakui, Yasutsugu Asai, Nobuhiro Dan, Yuki Takeda, Nobuo Ueki, Takahumi Otsuka, Nobuyuki Oba, Shuta Nisinakagawa, Tatsuya Kojima

“…An 85-year-old woman was an outpatient treated at Tokyo Rosai Hospital for cirrhosis caused by hepatitis B. She had previously been diagnosed as having common bile duct stones, for which she underwent endoscopic retrograde cholangiopancreatography (ERCP). …”
Get full text

The role of the interleukin family in liver fibrosis by Zixin Zhang, Zixin Zhang, Jiahui Wang, Hui Li, Qun Niu, Qun Niu, Yujing Tao, Yujing Tao, Xin Zhao, Xin Zhao, Zijian Zeng, Zijian Zeng, Haijian Dong, Haijian Dong

“…It is a critical step in the progression from chronic liver disease to cirrhosis and hepatocellular carcinoma. No chemical or biological drugs have been approved for the treatment of liver fibrosis. …”
Get full text

Retrospective study of the frequency of diagnosing diffuse changes in the liver parenchyma according to the results of radiological studies by N.Yu. Ziuz, V.M. Bogomaz

“…Given the variety of factors contributing to the progression of chronic liver diseases and the importance of identifying patients at high risk of developing liver cirrhosis, there is a need for widespread implementation of non-invasive diagnostic tests and technical upgrading of specialized healthcare facilities. …”
Get full text

Livogrit mitigates ANIT-induced cholestasis-like symptoms in an in vivo model by curbing hepatic inflammation and regulating BAX, TGF-β, MMP-9 and α-SMA gene expression by Acharya Balkrishna, Ritu Paliwal, Surjeet Singh, Rani Singh, Vivek Gohel, Rishabh Dev, Kunal Bhattacharya, Sandeep Sinha, Anurag Varshney

“…Bile duct constriction disrupts bile acid flow causing cholestasis, hepatic necrosis, fibrosis, and cirrhosis. The study investigated hepatoprotective effectiveness of Ayurvedic prescription herbal medicine “Livogrit” commercially available in India, against α-naphtylisothiocyanate (ANIT)-induced cholestasis-like symptoms in male Sprague-Dawley rats. …”
Get full text

Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases by Marilena Durazzo, Arianna Ferro, Victor Manuel Navarro-Tableros, Andrea Gaido, Paolo Fornengo, Fiorella Altruda, Renato Romagnoli, Søren K. Moestrup, Pier Luigi Calvo, Sharmila Fagoonee

“…Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack of clinically validated early-stage biomarkers and the limited availability of effective anti-fibrotic therapies. …”
Get full text

Acute-on-Chronic Liver Failure in Pregnant Patients with Chronic Hepatitis B: A Retrospective Observational Case Series Study by Shiwei Wang, Haofeng Xiong, Changling Luo, Hong Zhao, Ying Fan, Ting Zhang, Lili Wang, Qi Wang, Wen Xie

“…Acute-on-chronic liver failure (ACLF) is common in patients with end-stage liver disease and chronic hepatitis B (CHB) or hepatitis B virus- (HBV-) related cirrhosis. To date, no uniform definition and management strategy are available for ACLF. …”
Get full text

The clinical role of blood coagulation and platelet receptors gene allelic variants in development of cryoglobulinemic vasculitis at chronic hepatitis C by Yekaterina Ye. Starostina, M. V. Sokolova, L. M. Samokhodskaya, T. П. Rozina, T. N. Krasnova, Ye. B. Yarovaya, N. A. Mukhin

“…Original study included overall 200 patients with CHCs and liver cirrhosis in its outcome, who were divided into 3 groups: patients without cryoglobulinemia (CG, n=123), those with asymptomatic cryoglobulinemia (ACG, n=40) and with cryoglobulinemic vasculitis (CGV, n=37). …”
Get full text

Identification of a postoperative survival scoring index for adult liver transplantation by Shuai Wang, Xiaohong Lin, Yefu Li, Zhonghao Xie, Ming Zhang, Yicheng Liang, Chuchen Zhu, Yuqi Dong, Ping Zeng, Xiaoshun He, Weiqiang Ju, Maogen Chen

“…Our index also functioned well in predicting long-term mortality, and it was more effective for patients with hepatitis B cirrhosis or hepatocellular carcinoma (HCC).Conclusions We constructed a simplified and effective postoperative survival scoring index to predict short-term complications and survival in adult LT patients.…”
Get full text